Health
Related: About this forumIvermectin ineffective in preventing severe COVID-19-study
Related: Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities (JAMA Internal Medicine)
Earlier DU thread: Clinical Data just out - Ivermectin does not work on Covid
______________________________________________________________________
Source: Reuters
Ivermectin ineffective in preventing severe COVID-19-study
Fri, February 18, 2022, 11:22 AM
(Reuters) - Malaysian researchers found that treatment with the anti-parasite drug ivermectin did not prevent patients with COVID-19 from becoming severely ill in a randomized clinical trial published in the JAMA Internal Medicine journal on Friday.
The researchers said their findings do not support the use of ivermectin for patients with COVID-19.
The study enrolled 490 patients with mild to moderate illness at 20 hospitals and a COVID-19 quarantine center in Malaysia. Everyone received standard care; half the group also received ivermectin.
Severe disease developed in 21.6% of the patients given ivermectin and in 17.3% of those who received only standard care, the researchers said. They defined severe disease as requiring oxygen to help with breathing.
There were no statistically significant differences between the groups in rates of ICU admission, need for mechanical ventilation, or death, according to the study.
-snip-
Read more: https://news.yahoo.com/ivermectin-ineffective-preventing-severe-covid-162202670.html
______________________________________________________________________
Source: JAMA Internal Medicine
Original Investigation
February 18, 2022
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
The I-TECH Randomized Clinical Trial
JAMA Intern Med. Published online February 18, 2022. doi:10.1001/jamainternmed.2022.0189
Key Points
Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities?
Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
-snip-
Read more: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362
SheltieLover
(59,605 posts)LetMyPeopleVote
(154,470 posts)elias7
(4,187 posts)Oh, but unfortunately, our amateur MAGAt researchers dont really have any medical literacy to understand what they read, where to look, what is valid vs invalid, etc.
Midnight Writer
(22,972 posts)Those doctors at the hospital she was in tried to take credit, but they were actually the ones who tried to stop her from taking the ivermectin that saved her life.